Protagenic Therapeutics, Inc. reported that on May 15, 2025, it acquired 100% of Phytanix Bio through a Share Exchange Agreement, expanding its pipeline with five preclinical drug candidates. This significant event strengthens its market position but carries typical risks associated with early development.